Additionally, a functional CD4 immunity also seems important; among 51 NSCLC patients treated with anti–PDL-1, those with an increased proportion of highly differentiated CD4 (THD: CD27− CD28low/−) had improved PFS/OS (93). The gene discussed is CD274; the disease is non-small cell lung carcinoma.